ClinicalTrials.gg

Program

CHF5993

A development code. Also written as “CHF5993 100/6/12.5 μg pMDI HFA-152a”, “CHF5993 200/6/12.5 μg pMDI HFA-152a” and “CHF 5993 100/6/12.5 µg”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by Chiesi Farmaceutici.

Furthest: phase 4, since Oct 12, 202111 company-led studies, 2 open or runningNext primary completion: Jun 3, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici112 open or runningphase 4since Oct 12, 2021May 20, 2014Jun 3, 2027phase 2 · NCT07301736

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2014First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT02287272 · 25 enrolled · Belgium
  2. Feb 3, 20162 phase 3 studies in AsthmaNCT02676089, NCT02676076
  3. Mar 31, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02743013 · 50 enrolled · Belgium
  4. Jan 25, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03197818 · 708 enrolled · China, South Korea, Taiwan
  5. Jun 6, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03590379 · 366 enrolled · Bulgaria
  6. Oct 12, 2021Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT05097014 · 106 enrolled · Germany
  7. Mar 28, 2023Phase 1 study in AsthmaNCT05830071 · 95 enrolled · United States
  8. Nov 13, 2023Phase 3 study in AsthmaNCT06264674 · 827 enrolled · Bulgaria, Czechia, Georgia and more
  9. Dec 11, 2025Phase 2 study in AsthmaNCT07301736 · 780 planned · Argentina, Bosnia and Herzegovina, Bulgaria and more
  10. Sep 18, 2026Phase 3 study in AsthmaNCT07858123 · 700 planned · Germany, Italy, Spain

Ahead

  1. Jun 3, 2027Primary completion: phase 2 study in AsthmaNCT07301736
  2. Jun 26, 2030Primary completion: phase 3 study in AsthmaNCT07858123

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07858123Asthma · Germany, Italy, Spain3Not yet recruitingJun 26, 2030700
NCT07301736Asthma · Argentina, Bosnia and Herzegovina, Bulgaria and more2RecruitingJun 3, 2027780
NCT06264674Asthma · Bulgaria, Czechia, Georgia and more3CompletedFeb 18, 2025827
NCT05830071Asthma · United States1CompletedOct 13, 202395
NCT05097014Pulmonary Disease, Chronic Obstructive · Germany4CompletedFeb 24, 2023106
NCT03590379Pulmonary Disease, Chronic Obstructive · Bulgaria2CompletedOct 16, 2018366
NCT03197818Pulmonary Disease, Chronic Obstructive · China, South Korea, Taiwan3CompletedMay 26, 2020708
NCT02743013Pulmonary Disease, Chronic Obstructive · Belgium1CompletedJul 201650
NCT02676089Asthma · Argentina, Belarus, Bulgaria and more3CompletedMay 28, 20181,437
NCT02676076Asthma · Germany3CompletedMay 17, 20181,155
NCT02287272Pulmonary Disease, Chronic Obstructive · Belgium1CompletedJul 201425

How it is read

Names in the registry

  • “CHF5993”, 2 entries
  • “CHF5993 100/6/12.5 μg pMDI HFA-152a”, 1 entry
  • “CHF5993 200/6/12.5 μg pMDI HFA-152a”, 1 entry
  • “CHF 5993 100/6/12.5 µg”, 1 entry
  • “CHF 5993 100/6/12.5”, 1 entry

Codes read as this program: CHF5993.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.